Data presented at this year?s American Association for Cancer Research (AACR) meeting show that Merck KGaA?s targeted cancer therapy Erbitux? (cetuximab) significantly prolongs progression-free survival and increases overall response rate in metastatic colorectal cancer patients.
A phase III trial of 1,298 colorectal cancer patients has found that a combination of the drugs cetuximab (Erbitux) and irinotecan showed a significant improvement in progression-free survival over just irinotecan alone, according to an international team of researchers.
Research presented today at the 2007 Annual Meeting of the American Association for Cancer Research confirmed that there is now an effective treatment option for colorectal cancer patients for whom all other treatment options have been exhausted — cetuximab.
Experts agree that people who have had three or more potentially precancerous adenomatous polyps removed during a colonoscopy should be “rescoped” in three years to make sure the polyps do not recur.
Genetic variations in the body’s immune system could play a role in making African Americans more susceptible to developing colon cancer, scientists have found.
Data demonstrating genetic differences in individuals? susceptibility to certain cancers as well as differences in how people respond to specific cancer treatments will take center stage when more than 17,000 scientists from around the world gather at the Los Angeles Convention Center April 14-18 for the 2007 Annual Meeting of the American Association for Cancer Research (AACR). Key data presented at the meeting will also include findings related to the safety and effectiveness of several new, high-profile cancer therapies and vaccines.
A leading expert on modern day management of cancer is calling for the implementation of proper procedures that would allow NHS patients to top up cancer care in the private sector.
Today Almac Diagnostics announced a major study analysing colorectal polyp tissue samples using its novel Colorectal Cancer DSA? microarray. The DSA? research tool focuses on the transcriptome of an individual disease, in this case colorectal cancer, and contains significant additional data, relevant to the disease of interest that is not available on other generic microarrays.
The European Commission approved Xeloda in combination with platinum-based chemotherapy, for first-line use in patients with advanced stomach cancer.
A study by biomedical scientists at the University of Leicester has revealed for the first time that rice bran could reduce the risk of intestinal cancer.